GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth

Reuters01-12

GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth

GeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112893074) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602249512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602249512","market":"us","top_or_hot":-1,"title":"GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGS\">GeneDx Holdings</a> Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112893074) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGS\">GeneDx Holdings</a> Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112893074) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3zSYTM:1","article_id":"2602249512","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602249512","pubTimestamp":1768221093,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","WGS":"GeneDx Holdings"},"translate_title":"GeneDx预计2026年收入将高达5.55亿美元，外显子组和基因组增长强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":0.9},"content_text":"GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth\n    \n\nGeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112893074) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602249512","isCrawlerRequest":true}